Fernanda Costa Svedman

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: RADIATION ONCOLOGY. 2024;19(1):74
Stereotactic body radiation therapy is beneficial for a subgroup of patients with urothelial cancer and solitary metastatic disease: a single institution real-world experience
Svedman FC; Holmsten K; Jawdat F; Hailom W; Alm D; Grozman V; Ullen A
Article: IMMUNO-ONCOLOGY AND TECHNOLOGY. 2024;22:100713
Effect of glucocorticoids for the management of immune-related adverse events on outcome in melanoma patients treated with immunotherapy-a retrospective and biomarker study.
Costa Svedman F; Liapi M; Månsson-Broberg A; Chatzidionysiou K; Egyhazi Brage S
Article: CLINICAL GENITOURINARY CANCER. 2023;21(6):e438-e448
Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era
Holmsten K; Eknert J; Ofverholm E; Papantoniou D; Jawdat F; Verbiene I; Laurell A; Janes E; Sandzen J; Wojtyna-Dziedzic E; Lagstam I; Soderkvist K; Svedman FC; Liedberg F; Bruzelius M; Fransson A-S; Kjellstrom S; Omland LH; Pappot H; Ullen A
Journal article: ANNALS OF ONCOLOGY. 2023;34:s1213-s1214
Stereotactic body radiotherapy (SBRT) of patients with oligometastatic urothelial cancer (UC): A single institution experience
Jawdat F; Svedman FC; Holmsten K; Grozman V; Alm D; Hailom WS; Ullen A
Article: JOURNAL OF CLINICAL ONCOLOGY. 2023;41(1):75-85
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
Arance A; De La Cruz-Merino L; Petrella TM; Jamal R; Ny L; Carneiro A; Berrocal A; Marquez-Rodas I; Spreafico A; Atkinson V; Svedman FC; Mant A; Khattak MA; Mihalcioiu C; Jang S; Cowey CL; Smith AD; Hawk N; Chen K; Diede SJ; Krepler C; Long GV
Journal article: IMMUNO-ONCOLOGY AND TECHNOLOGY. 2022;16:100328
217P Characterization of immune cells in the tumor microenvironment of advanced bladder cancer
Flaberg E; Turkki R; Paavolainen L; Krantz D; Välimäki K; Schoonenberg A; Moussaud E; Holmsten K; Svedman FC; Kallioniemi O; Abrahamsson J; Liedberg F; Sjödahl G; Pellinen T; Ullén A; Östling P
Article: CANCERS. 2022;14(15):3587
Proliferation and Immune Response Gene Signatures Associated with Clinical Outcome to Immunotherapy and Targeted Therapy in Metastatic Cutaneous Malignant Melanoma
Svedman FC; Das I; Tuominen R; Ramqvist ED; Hoiom V; Brage SE
Article: CANCERS. 2022;14(3):702
Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors
Costa Svedman F; Jalsenius M; Hoeiom V; Grozman V; Bergqvist M; Soederdahl F; Eriksson H; Rotstein S; Ny L; Ascierto PA; Brage SE; Helgadottir H
Article: LAKARTIDNINGEN. 2021;118:21115
[Overview of immune-related side effects from immune checkpoint inhibitors. Part 1: Gastrointestinal, lung and kidney toxicity].
Villabona Lisa Villabona L; Costa Svedman F; Jovanovic B; Kaneteg B; Eberhardson M; Magin H; Ullenhag G; Blomqvist L; Helgadottir H
Article: CANCER RESEARCH. 2021;81(9):2545-2555
Inflammation and Apolipoproteins Are Potential Biomarkers for Stratification of Cutaneous Melanoma Patients for Immunotherapy and Targeted Therapy
Karlsson MJ; Svedman FC; Tebani A; Kotol D; Hoiom V; Fagerberg L; Edfors F; Uhlen M; Brage SE; Maddalo G
Article: CELL DEATH AND DISEASE. 2019;10(9):663
Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status
Das I; Wilhelm M; Hoiom V; Marquez RF; Svedman FC; Hansson J; Tuominen R; Brage SE
Article: PLOS ONE. 2018;13(11):e0206942
Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastastic cutaneous malignant melanoma
Svedman FC; Lohcharoenkal W; Bottai M; Brage SE; Sonkoly E; Hansson J; Pivarcsi A; Eriksson H
Article: CELL DEATH AND DISEASE. 2017;8(8):e3029
Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells
Azimi A; Tuominen R; Svedman FC; Caramuta S; Pernemalm M; Stolt MF; Kanter L; Kharaziha P; Lehtio J; Johansson CH; Holom V; Hansson J; Brage SE
Article: SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY. 2009;43(2):98-103
Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines
Ullen A; Schwarz S; Lennartsson L; Kalkner K-M; Sandstrom P; Costa F; Lennernas B; Linder S; Nilsson S
Article: CLINICS. 2009;64(7):641-644
PROSTASIN, A POTENTIAL TUMOR MARKER IN OVARIAN CANCER- A PILOT STUDY
Costa FP; Batista Junior EL; Zelmanowicz A; Svedman C; Devenz G; Alves S; Martins da Silva AS; Garicochea B

Alla övriga publikationer

Conference publication: ANNALS OF ONCOLOGY. 2023;34:s688-s689
Association of immune-related adverse events (irAE) requiring glucocorticoids (GCs) with outcome and biomarkers in advanced cutaneous malignant melanoma (CMM) treated with immune checkpoint inhibitors (ICI)
Svedman FC; Liapi M; Chatzidionysiou A; Mansson-Broberg A; Brage SE
Letter: ACTA ONCOLOGICA. 2022;61(9):1116-1120
Dynamics of plasma thymidine kinase activity in metastatic melanoma reflects immune checkpoint inhibitor efficacy
Costa Svedman F; Jalsenius M; Grozman V; Bergqvist M; Soderdahl F; Rotstein S; Ny L; Egyhazi Brage S; Helgadottir H
Meeting abstract: ANNALS OF ONCOLOGY. 2022;33(7):S945
Inflammation proteins associated with worse clinical outcome to treatment with anti-PD1 in metastatic cutaneous melanoma
Svedman FC; Helgadottir H; Brage SE
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2021;39(15):9504
Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004.
Arance AM; de la Cruz-Merino L; Petrella TM; Jamal R; Ny L; Carneiro A; Berrocal A; Marquez-Rodas I; Spreafico A; Atkinson V; Svedman FC; Mant A; Smith AD; Chen K; Diede SJ; Krepler C; Long GV
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2021;39(15):9556
Plasma thymidine kinase activity (TKa) as a novel prognostic biomarker in metastatic melanoma.
Helgadottir H; Svedman FC; Jalsenius M; Hoiom V; Rotstein S; Brage SE; Grozman V; Soderdahl F; Ny L; Bergqvist M
Thesis / dissertation: 2021
Molecular markers for prediction of response and progression free survival to novel therapies in cutaneous malignant melanoma
Costa Svedman, Fernanda
Conference publication: ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. 2021;17:66-67
LEAP-004: updated data for lenvatinib plus pembrolizumab in patients with advanced melanoma and confirmed progressive disease on a prior PD-(L)1 inhibitor
Long GV; de la Cruz-Merino L; Petrella TM; Jamal R; Ny L; Carneiro A; Berrocal A; Marquez Rodas I; Spreafico A; Atkinson V; Costa Svedman F; Mant A; Smith AD; Chen K; Diede S; Krepler C; Arance A
Meeting abstract: ANNALS OF ONCOLOGY. 2020;31:S1173
Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004
Arance Fernandez AM; O'Day SJ; de la Cruz Merino L; Petrella T; Jamal R; Ny L; Carneiro A; Berrocal A; Marquez-Rodas I; Spreafico A; Atkinson VV; Svedman FC; Smith AD; Chen K; Diede SJ; Krepler C; Long GV
Letter: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2017;31(6):e280
Response to 'Surgical outcomes reflect the histological types of cutaneous malignant melanoma'
Svedman FC
Review: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2017;31(4):603-615
Surgical outcomes in patients with cutaneous malignant melanoma in Europe - a systematic literature review
Svedman FC; Spanopoulos D; Taylor A; Amelio J; Hansson J
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(15):9579
Exosomal microRNAs as putative predictive biomarkers for targeted therapy in stage IV cutaneous malignant melanoma (CMM).
Eriksson H; Lohcharoenkal W; Costa-Svedman F; Sonkoly E; Brage SE; Hansson J; Pivarcsi A
Review: CLINICAL EPIDEMIOLOGY. 2016;8:109-122
Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe - a systematic review of the literature
Svedman FC; Pillas D; Taylor A; Kaur M; Linder R; Hansson J
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2014;32(15):e17004
The ACCROBAT I study: Three-year follow-up of a prospective phase II study with neoadjuvant TPF before bioradiotherapy for stage III-IV unresectable squamous cell head and neck cancer
Mercke C; Sjodin H; Haugen H; Wickart-Johansson G; Costa-Svedman F; von Dobeln G; Margolin G; Hellstrom M; Nyman J
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2010;28(15):5581
Toxicity and one-year tumor control with induction chemotherapy and bioradiotherapy for locally advanced unresectable head and neck cancer
Mercke C; Haugen H; Adell G; Costa-Svedman F; Nyman J; Wickart-Johansson G; Sjodin H

Anställningar

Anknuten till Forskning, Onkologi-Patologi, Karolinska Institutet, 2023-2026

Examina och utbildning

Medicine Doktorsexamen, Institutionen för onkologi-patologi, Karolinska Institutet, 2021

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI